A Randomized Phase III Clinical Study of Entinostat/Placebo in Combination With Exemestane in Chinese Patients With Hormone Receptor-positive Advanced Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Entinostat (Primary) ; Exemestane (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Eddingpharm
- 03 May 2019 Planned number of patients changed from 512 to 327.
- 03 May 2019 Planned End Date changed from 1 Apr 2023 to 1 Aug 2021.
- 03 May 2019 Planned primary completion date changed from 1 Oct 2020 to 1 Feb 2021.